Prot #2215-CL-9100: A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3 Mutated AML in Complete Remission (CR) with M

Project: Research project

Project Details

StatusActive
Effective start/end date9/20/179/20/20

Funding

  • INC Research, LLC (Prot #2215-CL-9100)
  • Astellas Pharma Global Development, Inc. (Prot #2215-CL-9100)